BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9130273)

  • 1. Current role of protective agents in cancer treatment.
    Schuchter LM
    Oncology (Williston Park); 1997 Apr; 11(4):505-12, 515-6; discussion 517-8. PubMed ID: 9130273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current role of chemotherapy protectors in cancer treatment.
    Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
    Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(1):22-8. PubMed ID: 17283738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(2):40-7. PubMed ID: 17405678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy: therapeutic potential in the age of growth factor support.
    Ariad S; Bezwoda WR
    Isr J Med Sci; 1992 Jun; 28(6):377-85. PubMed ID: 1607279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
    Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
    Cairo MS
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical use of colony stimulating factors.
    Moore MA
    Annu Rev Immunol; 1991; 9():159-91. PubMed ID: 1910675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with cytoprotective agents and radiotherapy.
    Winczura P; Jassem J
    Cancer Treat Rev; 2010 May; 36(3):268-75. PubMed ID: 20044209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the administration of amifostine.
    Schuchter LM
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
    Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
    Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of cancer chemotherapy. Cytoprotective agents].
    Lopez M
    Clin Ter; 2001; 152(2):135-43. PubMed ID: 11441524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.